{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:46:58Z","timestamp":1780051618468,"version":"3.53.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.bcp.2004.08.012","type":"journal-article","created":{"date-parts":[[2004,9,29]],"date-time":"2004-09-29T11:08:18Z","timestamp":1096456098000},"page":"1-5","source":"Crossref","is-referenced-by-count":30,"title":["Lisofylline: a potential lead for the treatment of diabetes"],"prefix":"10.1016","volume":"69","author":[{"given":"Zandong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry L.","family":"Nadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2004.08.012_bib1","first-page":"1174","article-title":"Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol","volume":"24","author":"Lillibridge","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2004.08.012_bib2","first-page":"337","article-title":"Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids","volume":"284","author":"Bursten","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2004.08.012_bib3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1021\/js970382f","article-title":"CYP3A4-mediated oxidation of lisofylline to lisofylline 4,5-diol in human liver microsomes","volume":"87","author":"Shin","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2004.08.012_bib4","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1073\/pnas.91.9.3857","article-title":"Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid","volume":"91","author":"Rice","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2004.08.012_bib5","first-page":"14","article-title":"Potential role for phosphatidic acid in mediating the inflammatory responses to TNF \u03b1 and IL-1\u03b2","volume":"44","author":"Bursten","year":"1994","journal-title":"Circ. Shock"},{"key":"10.1016\/j.bcp.2004.08.012_bib6","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1210\/endo.137.11.8895359","article-title":"Lisofylline, an inhibitor of unsaturated phosphatidic acid generation, ameliorates interleukin-l\u03b2-induced dysfunction in cultured rat islets","volume":"137","author":"Bleich","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2004.08.012_bib7","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1172\/JCI118350","article-title":"Skeletal muscle membrane lipid composition is related to adiposity and insulin action","volume":"96","author":"Pan","year":"1995","journal-title":"J. Clin. Invest."},{"issue":"Suppl 5","key":"10.1016\/j.bcp.2004.08.012_bib8","article-title":"Skeletal muscle membrane lipids and insulin resistance","volume":"31","author":"Storlien","year":"1996","journal-title":"Lipids"},{"issue":"Suppl 7","key":"10.1016\/j.bcp.2004.08.012_bib9","article-title":"Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids","volume":"31","author":"Kremer","year":"1996","journal-title":"Lipids"},{"key":"10.1016\/j.bcp.2004.08.012_bib10","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/00003246-199607000-00011","article-title":"An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndrome","volume":"24","author":"Bursten","year":"1996","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.bcp.2004.08.012_bib11","first-page":"776","article-title":"Effects of lisofylline on hyperoxia-induced lung injury","volume":"276","author":"George","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.bcp.2004.08.012_bib12","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/ajrccm.155.3.9117028","article-title":"The effects of post-treatment with lisofylline, a phosphatidic acid generation inhibitor, on sepsis-induced acute lung injury in pigs","volume":"155","author":"Hasegawa","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bcp.2004.08.012_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/jsre.1998.5453","article-title":"Selective downregulation of neutrophils by a phosphatidic acid generation inhibitor in a porcine sepsis model","volume":"81","author":"Oka","year":"1999","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.bcp.2004.08.012_bib14","first-page":"966","article-title":"Modulating phosphatidic acid metabolism decreases oxidative injury in rat lungs","volume":"273","author":"Guidot","year":"1997","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.bcp.2004.08.012_bib15","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1097\/00003246-199610000-00021","article-title":"Lisofylline decreases white cell adhesiveness and improves survival after experimental hemorrhagic shock","volume":"24","author":"Waxman","year":"1996","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.bcp.2004.08.012_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00024382-199904000-00008","article-title":"Lisofylline ameliorates intestinal mucosal barrier dysfunction caused by ischemia and ischemia\/reperfusion","volume":"11","author":"Wattanasirichaigoon","year":"1999","journal-title":"Shock"},{"key":"10.1016\/j.bcp.2004.08.012_bib17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1097\/00003246-200005000-00047","article-title":"Lisofylline ameliorates intestinal and hepatic injury induced by hemorrhage and resuscitation in rats","volume":"28","author":"Wattanasirichaigoon","year":"2000","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.bcp.2004.08.012_bib18","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1210\/endo.143.6.8841","article-title":"Lisofylline, a novel anti-inflammatory agent, protects pancreatic \u03b2-cells from pro-inflammatory cytokine damage by promoting mitochondrial metabolism","volume":"143","author":"Chen","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2004.08.012_bib19","first-page":"105","article-title":"Lisofylline inhibits transforming growth factor beta release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice","volume":"56","author":"Clarke","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2004.08.012_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.1998.4972","article-title":"Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II)","volume":"70","author":"Husain","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bcp.2004.08.012_bib21","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0301-472X(00)00493-8","article-title":"Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents","volume":"28","author":"de Vries","year":"2000","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bcp.2004.08.012_bib22","first-page":"513","article-title":"Lisofylline as a modifier of radiation therapy","volume":"8","author":"Wong","year":"1996","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bcp.2004.08.012_bib23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.bmt.1702114","article-title":"A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The lisofylline marrow transplant study group","volume":"25","author":"List","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bcp.2004.08.012_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00024382-199404000-00003","article-title":"CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo","volume":"1","author":"Rice","year":"1994","journal-title":"Shock"},{"key":"10.1016\/j.bcp.2004.08.012_bib25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1365-2567.1997.00252.x","article-title":"Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-\u03b1, IL-\u03b2, IL-10 by human leucocytes","volume":"91","author":"van Furth","year":"1997","journal-title":"Immunology"},{"key":"10.1016\/j.bcp.2004.08.012_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0165-5728(00)00348-9","article-title":"Amelioration of CR-EAE with lisofylline: effects on mRNA levels of IL-12 and IFN-\u03b3 in the CNS","volume":"110","author":"Du","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2004.08.012_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.iy.13.040195.001343","article-title":"Interleukin-12: a pro-inflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity","volume":"13","author":"Trinchieri","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2004.08.012_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/382171a0","article-title":"Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells","volume":"382","author":"Thierfelder","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2004.08.012_bib29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/382174a0","article-title":"Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice","volume":"382","author":"Kaplan","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2004.08.012_bib30","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1084\/jem.181.2.817","article-title":"Interleukin-12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice","volume":"181","author":"Trembleau","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2004.08.012_bib31","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2004.08.012_bib32","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.4049\/jimmunol.161.12.7015","article-title":"Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signalling and IL-12-mediated Thl differentiation: an effect of the novel anti-inflammatory drug lisofylline","volume":"161","author":"Bright","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2004.08.012_bib33","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.4049\/jimmunol.163.12.6567","article-title":"Selective pharmacologic inhibition of murine and human IL-12-dependent Thl differentiation and IL-12 signalling","volume":"163","author":"Coon","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2004.08.012_bib34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1196\/annals.1288.069","article-title":"Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes","volume":"1005","author":"Yang","year":"2003","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.bcp.2004.08.012_bib35","first-page":"1","article-title":"Breeding of a non-obese, diabetic strain of mice","volume":"29","author":"Makino","year":"1980","journal-title":"Jikken Dobutsu. Exp. Anim."},{"key":"10.1016\/j.bcp.2004.08.012_bib36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0065-2776(08)60490-3","article-title":"The murine autoimmune diabetes model: NOD and related strains","volume":"51","author":"Kikutani","year":"1992","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.bcp.2004.08.012_bib37","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00125-002-0901-y","article-title":"The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice","volume":"45","author":"Yang","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2004.08.012_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2337\/diab.42.1.44","article-title":"Adoptive transfer of diabetes into immunodeficient NOD-scid\/scid mice Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD. NON-Thy-la donors","volume":"42","author":"Christianson","year":"1993","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2004.08.012_bib39","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.4049\/jimmunol.172.7.4245","article-title":"IFN-\u03b3 stimulates the expression of a novel Secretoglobin that regulates chemotactic cell migration and invasion","volume":"172","author":"Choi","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2004.08.012_bib40","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1097\/00006676-200305000-00021","article-title":"The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice","volume":"26","author":"Yang","year":"2003","journal-title":"Pancreas"},{"key":"10.1016\/j.bcp.2004.08.012_bib41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.180605","article-title":"Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus","volume":"193","author":"Like","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.bcp.2004.08.012_bib42","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2337\/diab.18.9.606","article-title":"Streptozotocin diabetes in the mouse and guinea pig","volume":"18","author":"Brosky","year":"1969","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2004.08.012_bib43","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2337\/diab.44.3.354","article-title":"Diabetes induced with low doses of streptozotocin is mediated by V beta 8.2+ T-cells","volume":"44","author":"Herold","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2004.08.012_bib44","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4049\/jimmunol.140.4.1111","article-title":"IFN-gamma induces islet cell MHC antigens and enhances autoimmune, streptozotocin-induced diabetes in the mouse","volume":"140","author":"Campbell","year":"1988","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2004.08.012_bib45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaut.2003.08.006","article-title":"Autoimmune diabetes is blocked in Stat4-deficient mice","volume":"22","author":"Yang","year":"2004","journal-title":"J. Autoimmun."},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2004.08.012_bib46","first-page":"455","article-title":"Inflammatory blockade improves human islet function in transplantation","volume":"53","author":"Yang","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2004.08.012_bib47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0962-8924(00)01803-1","article-title":"Mitochondria as the central control point of apoptosis","volume":"10","author":"Desagher","year":"2000","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bcp.2004.08.012_bib48","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s001250050044","article-title":"\u03b2-cell mitochondria in the regulation of insulin secretion: a new culprit in Type II diabetes","volume":"43","author":"Wollheim","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2004.08.012_bib49","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/00007890-199604270-00027","article-title":"Evidence of recurrent autoimmunity in human allogeneic islet transplantation","volume":"61","author":"Stegall","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.bcp.2004.08.012_bib50","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1196\/annals.1288.016","article-title":"Islet cell autoimmunity and transplantation tolerance: two distinct mechanisms?","volume":"1005","author":"Pearson","year":"2003","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.bcp.2004.08.012_bib51","first-page":"227","article-title":"The role of autoimmunity in the pathogenesis of lung allograft rejection","volume":"51","author":"Wilkes","year":"2003","journal-title":"Archivum Immunologiae et Therapiae Experimentalis"},{"key":"10.1016\/j.bcp.2004.08.012_bib52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/jhep.2002.35339","article-title":"Autoimmunity after liver transplantation","volume":"36","author":"Vergani","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2004.08.012_bib53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF03345166","article-title":"Development of Graves\u2019 disease in a patient under immunosuppressive therapy after liver transplantation","volume":"26","author":"Bednarczuk","year":"2003","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.bcp.2004.08.012_bib54","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/jlts.2001.24638","article-title":"Successful tacrolimus therapy for a severe recurrence of Type 1 autoimmune hepatitis in a liver graft recipient","volume":"7","author":"Hurtova","year":"2001","journal-title":"Liver Transpl."},{"key":"10.1016\/j.bcp.2004.08.012_bib55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s002680020341","article-title":"Human islet transplantation: update","volume":"25","author":"Boker","year":"2001","journal-title":"World J. Surg."},{"key":"10.1016\/j.bcp.2004.08.012_bib56","first-page":"215","article-title":"Evidence of recurrent Type I diabetes following HLA-mismatched pancreas transplantation","volume":"26","author":"Petruzzo","year":"2000","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.bcp.2004.08.012_bib57","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00007890-200003270-00016","article-title":"Human islet transplantation: lessons from 13 autologous and 13 allogeneic transplantations","volume":"69","author":"Oberholzer","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.bcp.2004.08.012_bib58","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/s-2000-8127","article-title":"Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506\/tacrolimus","volume":"108","author":"Lohmann","year":"2000","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.bcp.2004.08.012_bib59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.TP.0000104844.48064.81","article-title":"The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation","volume":"77","author":"Yang","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.bcp.2004.08.012_bib60","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1210\/en.2003-0739","article-title":"Lisofylline a novel anti-inflammatory compound, protects mesangial cells from hyperglycemia-and angiotensin II-mediated extracellular matrix deposition","volume":"144","author":"Bolick","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2004.08.012_bib61","first-page":"123","article-title":"The role of the mesangial cell and its matrix in the pathogenesis of diabetic nephropathy","volume":"45","author":"McLennan","year":"1999","journal-title":"Cell. Mol. Biol."},{"key":"10.1016\/j.bcp.2004.08.012_bib62","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1152\/ajprenal.00300.2002","article-title":"TGF-beta signal transduction and mesangial cell fibrogenesis","volume":"284","author":"Schnaper","year":"2003","journal-title":"Am. J. Physiol. Renal Fluid Electrolyte Physiol."},{"key":"10.1016\/j.bcp.2004.08.012_bib63","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1152\/ajprenal.00181.2002","article-title":"Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells","volume":"283","author":"Reddy","year":"2002","journal-title":"Am. J. Physiol. Renal Fluid Electrolyte Physiol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295204005908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295204005908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T07:35:34Z","timestamp":1682753734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295204005908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0006295204005908"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2004.08.012","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}